The GnRH analogue triptorelin confers ovarian radio-protection to adult female rats.
There is a controversy regarding the effects of the analogues of the gonadotrophin-releasing hormone (GnRH) in radiotherapy. This has led us to study the possible radio-protection of the ovarian function of a GnRH agonist analogue (GnRHa), triptorelin, in adult, female rats (Rattus norvegicus sp.). The effects of the X-irradiation on the oocytes of ovarian primordial follicles, with and without GnRHa treatment, were compared, directly in the female rats (F(0)) with reproductive parameters, and in the somatic cells of the resulting foetuses (F(1)) with cytogenetical parameters. In order to do this, the ovaries and uteri from 82 females were extracted for the reproductive analysis and 236 foetuses were obtained for cytogenetical analysis. The cytogenetical study was based on the data from 22,151 metaphases analysed. The cytogenetical parameters analysed to assess the existence of chromosomal instability were the number of aberrant metaphases (2234) and the number (2854) and type of structural chromosomal aberrations, including gaps and breaks. Concerning the reproductive analysis of the ovaries and the uteri, the parameters analysed were the number of corpora lutea, implantations, implantation losses and foetuses. Triptorelin confers radio-protection of the ovaries in front of chromosomal instability, which is different, with respect to the single and fractioned dose. The cytogenetical analysis shows a general decrease in most of the parameters of the triptorelin-treated groups, with respect to their controls, and some of these differences were considered to be statistically significant. The reproductive analysis indicates that there is also radio-protection by the agonist, although minor to the cytogenetical one. Only some of the analysed parameters show a statistically significant decrease in the triptorelin-treated groups.
Camats
N
N
Institut de Biotecnologia i de Biomedicina (I.B.B.), Universitat Autònoma de Barcelona, Barcelona, Spain.
García
F
F
Parrilla
J J
JJ
Calaf
J
J
Martín-Mateo
M
M
Caldés
M Garcia
MG
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D005260:Female; D009865:Oocytes / Q000528:radiation effects; D010053:Ovary / Q000528:radiation effects*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012098:Reproduction / Q000235:genetics / Q000528:radiation effects*; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014599:Uterus / Q000528:radiation effects; D014965:X-Rays / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D011837:Radiation-Protective Agents; D017329:Triptorelin Pamoate